These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 25436583

  • 1. Human neuronal cells: epigenetic aspects.
    Kukucka J, Wyllie T, Read J, Mahoney L, Suphioglu C.
    Biomol Concepts; 2013 Aug; 4(4):319-33. PubMed ID: 25436583
    [Abstract] [Full Text] [Related]

  • 2. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
    Ganai SA, Banday S, Farooq Z, Altaf M.
    Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
    [Abstract] [Full Text] [Related]

  • 3. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF, Dexter DT.
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [Abstract] [Full Text] [Related]

  • 4. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review.
    Vahid F, Zand H, Nosrat-Mirshekarlou E, Najafi R, Hekmatdoost A.
    Gene; 2015 May 10; 562(1):8-15. PubMed ID: 25701602
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Epigenetics in Neurodegenerative Diseases: The Role of Histone Deacetylases.
    Sharma S, Sarathlal KC, Taliyan R.
    CNS Neurol Disord Drug Targets; 2019 May 10; 18(1):11-18. PubMed ID: 30289079
    [Abstract] [Full Text] [Related]

  • 7. Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?
    Fischer A.
    Neuropharmacology; 2014 May 10; 80():95-102. PubMed ID: 24486385
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.
    Anne-Laurence B, Caroline R, Irina P, Jean-Philippe L.
    Subcell Biochem; 2007 May 10; 41():263-93. PubMed ID: 17484132
    [Abstract] [Full Text] [Related]

  • 12. A role for histone deacetylases in the cellular and behavioral mechanisms underlying learning and memory.
    Mahgoub M, Monteggia LM.
    Learn Mem; 2014 Oct 10; 21(10):564-8. PubMed ID: 25227251
    [Abstract] [Full Text] [Related]

  • 13. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis.
    Saha RN, Pahan K.
    Cell Death Differ; 2006 Apr 10; 13(4):539-50. PubMed ID: 16167067
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y, Seto E.
    Cold Spring Harb Perspect Med; 2016 Oct 03; 6(10):. PubMed ID: 27599530
    [Abstract] [Full Text] [Related]

  • 18. HDAC modulation and cell death in the clinic.
    Dell'Aversana C, Lepore I, Altucci L.
    Exp Cell Res; 2012 Jul 01; 318(11):1229-44. PubMed ID: 22336671
    [Abstract] [Full Text] [Related]

  • 19. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
    Swaminathan V, Reddy BA, Ruthrotha Selvi B, Sukanya MS, Kundu TK.
    Subcell Biochem; 2007 Jul 01; 41():397-428. PubMed ID: 17484138
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.